Standardization of the teratoma assay for analysis of pluripotency of human ES cells and biosafety of their differentiated progeny.
Teratoma tumor formation is an essential criterion in determining the pluripotency of human pluripotent stem cells. However, currently there is no consistent protocol for assessment of teratoma forming ability. Here we present detailed characterization of a teratoma assay that is based on subcutaneo...
Main Authors: | Michal Gropp, Vitali Shilo, Gilad Vainer, Miri Gov, Yaniv Gil, Hanita Khaner, Limor Matzrafi, Maria Idelson, Juri Kopolovic, Naomi B Zak, Benjamin E Reubinoff |
---|---|
Format: | Article |
Language: | English |
Published: |
Public Library of Science (PLoS)
2012-01-01
|
Series: | PLoS ONE |
Online Access: | http://europepmc.org/articles/PMC3458078?pdf=render |
Similar Items
-
Hadassah, provider of 'Regulatory-Ready' pluripotent clinical-grade stem cell banks
by: Shelly E Tannenbaum, et al.
Published: (2020-01-01) -
Murine pluripotent stem cells that escape differentiation inside teratomas maintain pluripotency
by: Yangli Pei, et al.
Published: (2018-01-01) -
Cisplatin induces differentiation in teratomas derived from pluripotent stem cells
by: Atsushi Kurata, et al.
Published: (2021-12-01) -
Defining the Skeletal Myogenic Lineage in Human Pluripotent Stem Cell-Derived Teratomas
by: Matthew P. Pappas, et al.
Published: (2022-05-01) -
Effects of low oxygen culture on pluripotent stem cell differentiation and teratoma formation
by: Millman, Jeffrey Robert
Published: (2011)